Cough and its treatment with the new peripherally-acting drug Levopront

Abstract

The efficacy and tolerability of new anti-coughing peripherally-acting drug Levopront (Levodropropizine) were studied in patients with dry cough. Data for 60 patients aged from 18 to 73 years with various respiratory diseases treated in 3 clinics were analyzed. Levopront was applied in a commonly recommended dose during 7 -10 days.
The efficacy of Levopront was 90 % and good or quite good results embodied in disappearance or significant reduction of cough were found in 80% of the cases. The drug's high efficacy was accompanied by its good tolerability. The adverse events displayed were not great and did not require the treatment abolition.
Thus, the results obtained evidence that Levopront (Levodropropizine) is an effective and safe drug for treatment of dry cough due to various respiratory pathology in patients of different age.